Audit: QRS - Thiamine for Health & Longevity

Audit conducted on 12/08/2026 11:23 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: protocol cells to ER lines 369–381, time cells to ER lines 185/424, benefits and risks to the ER tier headings, gates to ER lines 317–345, monitoring table to ER lines 450–467.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Neither approach is established as the default” (action_2_sub) mirrors ER line 371; at_a_glance “have left blood sugar, heart function, and nerve damage untouched” mirrors ER line 491.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	All four ER “Populations who should avoid” entries stay in the Contraindications gate; no interaction is upgraded or downgraded relative to ER lines 317–335.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come only from ER lines 339–345, Key Interactions only from ER lines 317–335; no Benefit- or Risk-Modifying Factor content appears in either gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, citations, expert names, NCT identifiers, or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighing register throughout, matching the ER’s framing of a narrow established use against a wider unsupported set of claims.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and dose ranges are paired with plain-language explanation in every “Why” cell and protocol sub-line.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated descriptively (“Conventional practice”, “Point at which fatigue and symptom changes were assessed in the trials”) rather than as instruction.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative directed at a reader; the gates and monitoring rows report ER findings rather than issuing instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instances of “recommended”, “advised”, “should”, or equivalent in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns occur anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical marker names are paired with plain “Why” explanations; at_a_glance uses “fluid tablets”, “weight-loss surgery” instead of clinical terms.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate and tier item is a compressed noun phrase; no item carries a trailing explanation.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by scan: no “you”, “your”, “we”, or “our” anywhere in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content is pitched at self-directed implementation: test-first cadence, functional ranges tighter than laboratory reference ranges, form selection.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Seven-marker monitoring panel and multi-point cadence assume a reader willing to test and retest.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges and split gram-level dosing are not general-population content.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	at_a_glance draws exactly the distinction that matters to this audience: repletion of a genuine shortfall works, high doses in the well-supplied did not.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears in the title and header; “anti-aging” does not appear in the document.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Body uses “parenteral dosing”, “erythrocyte transketolase activation coefficient”, “alanine aminotransferase”; the plain-language wording in at_a_glance is the ER’s own Conclusion phrasing and is required by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings present verbatim at lines 440, 477, 519, 568, 587, 684; gate headings at lines 539 and 548; tier labels at lines 522–531 and 571–580; column headers at lines 591–593.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	61 uniquely named data-qrs-var spans present, each exactly once, covering title, header, at-a-glance, three action sets, three time sets, four benefit tiers, both gates, four risk tiers, seven marker rows, cadence, and six qualitative items.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The non-variable template spans website="evidence_review", website="audit" (lines 423, 426) and website="full_review" (line 434) are untouched and empty as in the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped by this template is empty; every benefit tier, risk tier, gate, and monitoring row has ER content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1/2/3_label reproduce the ER bold labels “Repletion dose for documented deficiency”, “Pharmacological approach”, “Choice of form” (ER lines 369, 371, 381); interaction items reproduce the ER bold interaction labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Where the ER supplies a label it is carried over unchanged; the time-to-effect labels are derived content required by item 11.4, since the ER supplies no per-aspect bold labels for that row.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters occur in the file; the ER’s 🟩/🟥/🟨 tier markers and the “⚠️ Conflicted” flags were correctly dropped in favour of CSS palettes and bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Thirteen ER protocol bullets are condensed to three action cells and thirteen ER monitoring/qualitative lines to compact table rows; no section carries prose beyond its cell budget.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14: the metadata comment immediately follows <!doctype html> on line 1 and precedes the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- on line 3, closing --- on line 13; the descriptive text on line 2 precedes the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block sits entirely inside an HTML comment; none of its values are repeated in head or body markup.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly, because it contains a colon; all other values are bare and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: thiamine_2026-0812-1016_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0812-1116, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number with no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: thiamine_2026-0812-1016_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all ten keys: no stray whitespace, no unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Thiamine for Health & Longevity - Quick Reference Sheet, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Thiamine for Health & Longevity.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 08/12/2026, the correct MM/DD/YYYY rendering of qrs_creation_date 2026-0812-1116.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter qrs_creator_ai_fullname.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block (lines 415–428) contains only the title and the template subline; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Line 433 compresses ER lines 489–493 into the decision-relevant split: repletion of a genuine shortfall works, high-dose use in the well-supplied did not, confirmatory trials pending.
7.2	[at_a_glance] is no longer than 60 words	🟢	55 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Safety record and shortfall list from ER line 489; untouched outcomes from ER line 491; two pending trials from ER line 493.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “fluid tablets”, “weight-loss surgery”, “poor absorption” carry the ER’s own plain-language substitutions for diuretics, bariatric surgery, and malabsorption.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size, or p-value appears; “Two large trials are pending” is unattributed.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimate of any kind in the span.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All four items map to the “Populations who should avoid Thiamine” list at ER lines 337–345.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All four ER avoid-populations are present (anaphylaxis/hypersensitivity, advanced kidney disease, suspected Wernicke encephalopathy, pregnancy and lactation above reference intakes); none is omitted or added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 541–544: four discrete <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s post-dash clauses (“absolute contraindication to re-exposure by any route”, “clearance is reduced and no dosing data exist”, “this requires parenteral treatment under medical supervision”, “dietary-level intake is established as necessary”) are all stripped; no item contains a dash.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The kidney threshold is retained as “(filtration rate below 30 mL/min/1.73 m²)” and the dose qualifiers “at gram-level doses” and “at doses above reference intakes” are kept.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication bullets use no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, as required, because ER lines 339–345 name four such populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items map one-to-one to the interaction bullets at ER lines 317–335.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interactions are carried; none duplicates a Contraindication entry, and alcohol is correctly kept here since the ER’s avoid list does not name it.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 550–559: ten discrete <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER Severity/Consequence/Mitigation clause and every citation is stripped; each item is a bare label with, at most, its example list.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Loop-diuretic, antacid, and supplement example lists are preserved verbatim, and the otherwise unusable labels “Other transporter-inhibiting prescription drugs” and “Other interventions” carry the ER’s named examples (fedratinib; bariatric surgery, prolonged parenteral nutrition, high-dose intravenous glucose).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, as required, because the ER names ten such interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets at lines 369, 371, 375, 379, and 381.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two competing dosing traditions (repletion 50–100 mg; pharmacological 300–1,800 mg) plus form selection are the decisions the ER itself frames as unresolved and consequential.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects and all three sets are populated.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Lines 444–473: all nine action spans carry ER-derived content; none is empty or placeholder.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Deficiency signs (hours to days) and chronic fatigue (4 weeks) from ER line 424; cognitive decline (12 months) from the ER’s 12-month benfotiamine trial at line 185.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the ER benefit tiers: deficiency correction (High), chronic fatigue (Medium), cognitive decline (Low).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects and all three sets are populated.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Lines 483–511: all nine time spans carry ER-derived content; none is empty or placeholder.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information (line 424), so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten items map to the ER Expected Benefits headings at lines 159–222.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 521–532 with the correct tier assignment for every item.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; all Magnitude figures, conflict flags, and trial descriptions are dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight items map to the ER risk headings at lines 246–297.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 570–581 with the correct tier assignment for every item.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; the reaction rates, mean differences, and mechanistic discussion are dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER Monitoring Protocol & Defining Success biomarker table at lines 450–458.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER rows are present with matching optimal ranges: thiamine diphosphate, transketolase activation coefficient, magnesium, alanine aminotransferase, fasting glucose/glycated haemoglobin, lactate, urinary albumin-to-creatinine ratio.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 678 carries the ER’s baseline, 4–8 week, 8–12 week, and 6–12 month schedule from ER line 448.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items come from the ER’s “Qualitative markers worth tracking alongside laboratory values” list at lines 462–467.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are reproduced verbatim in qualitative_item_1 through qualitative_item_6.

Issues 12/08/2026 11:23

Pass rate 100.00%. No issues found.